Breast cancer remains one of the most prevalent and concerning diseases affecting women worldwide. In recent years, advancements in diagnostic technologies have revolutionized the detection and management of breast cancer. From innovative imaging techniques to genetic testing, the breast cancer diagnostics market has witnessed remarkable growth, contributing to early detection and improved patient outcomes. In this blog post, we will explore the dynamic landscape of the breast cancer diagnostics market, highlighting key trends, advancements, challenges, and future prospects.
Demand for early detection of breast cancer is seeing a major rise as people are seeking more efficient diagnostic solutions to deal with the disease effectively. Apart from other tests to detect breast cancer, imaging and screening have also seen substantial rise in popularity. Screening for breast cancer is deemed effective, but some methods are still being debated whether they are safe and accurate for prolonged use.
Download a sample copy of this report:–https://www.factmr.com/connectus/sample?flag=S&rep_id=55?PJ
Key Takeaways from the Market Study
By test type, CEA test expected to hold more than 45% market share for breast cancer diagnostics
By end user, hospital based labs expected to hold more than 50% market share for breast cancer diagnostics market.
Breast cancer diagnostics industry expected to possess nearly 45% market share throughout North America.
Breast cancer diagnostics industry expected to possess nearly 40% market share throughout Asia Pacific.
Global market for breast cancer diagnostics to reach US$ 4 Bn by the end of 2022
Early Detection Bolstering Demand for Breast Cancer Diagnostics?
The number of breast cancer cases across the globe is rising rapidly and has become the most common type of cancer in 2021. Early detection of breast cancer tumours is one of the major challenges in diagnosis and treatment, as in most cases, they are detected after they have grown to an advanced stage.
Demand for early detection of breast cancer is seeing a major rise as people are seeking more efficient diagnostic solutions to deal with the disease effectively. Apart from other tests to detect breast cancer, imaging and screening have also seen substantial rise in popularity. Screening for breast cancer is deemed effective, but some methods are still being debated whether they are safe and accurate for prolonged use.
Market Players: –
Bio-Rad Labs Inc.
Illumina Co., Ltd.
Biocept Co., Ltd.
Epigenomics AG
AstraZeneca PLC
Myriad Genetics Inc.
Quest diagnostic integration.
competitive landscape
Major providers of breast cancer diagnosis are committed to providing diagnostic solutions that provide early detection of breast cancer. Key market players are also investing in research and development of fast, accurate and cost-effective diagnostic solutions.
In September 2021, Vice President of India Shri M. Venkaiah Naidu launched the first breast cancer helpline established by Ushalakshmi Breast Cancer Foundation. This is a new step for the country to spread breast cancer awareness.
Actress and model Elizabeth Hurley opened a cancer support center in London in September 2021 ahead of Cancer Awareness Month. The support center was named Future Dreams House.
In October 2021, to raise awareness of breast cancer, WellSpan Health and Capital Blue Cross have teamed up to launch a mobile mammography motor coach with the goal of increasing breast cancer screening in five countries.
Major Segments Covered in Breast Cancer Diagnosis Report
By test type
CA test for breast cancer
BRCA test for breast cancer
ER & PR tests for breast cancer
CEA test for breast cancer
KRAS mutation screening for breast cancer
HER 2 test for breast cancer
PSA test for breast cancer
EGFR mutation screening for breast cancer
Immunohistochemistry for breast cancer
etc
By end user
Hospital related laboratory
independent diagnostic lab
cancer research institute
etc
Regional analysis includes:
North America (USA, Canada)
Latin America (Brazil, Mexico, Argentina, Chile, Peru, rest of LATAM)
EU – (Germany, France, Italy, Spain), UK, Benelux (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Republic, etc.), Rest of Europe
CIS and Russia
Japan
Asia Pacific excluding Japan (Greater China, India, Korea, ASEAN countries, rest of APEJ)